They Sold Their Company to Boston Scientific and Then Reacquired the Technology Years Later: The Unique Story of NuCryo Vascular

Interview with Kevin Beedon

Because of diminishing margins, a lot of major medical device companies continue to add products to their sales bag in hopes of meeting top-line revenue goals. But selling the entire bag is challenging.

When the bag gets too big, a typical sales force will usually focus only on products that generate the most revenue. So what happens to those products that don’t produce much revenue? Well, they’re sometimes just lost in the dust.

In this interview with Kevin Beedon, General Manager of NuCryo Vascular, we learn how their team is taking advantage of this very scenario as they look to commercialize the newly redesigned PolarCath device.

Interview Highlights with Kevin Beedon

  • Why the founders of NuCryo Vascular decided to reacquire the technology they originally sold to Boston Scientific just years earlier.

  • After initially signing a distribution deal with Vascular Solutions, why the team at NuCryo Vascular decided to go with a direct sales force instead.

  • How the team at NuCryo Vascular was able to quickly make engineering changes to the PolarCath device and then get FDA approval only 40 days later

  • Kevin’s advice for making career changes within the medical device space.

  • Kevin’s favorite business book, the business leader he most admires, and the advice he’d give to his 30-yr. old self.

Premium Members Only

Premium Members Only

You don't have access to this post, but if you become a premium member, you'll be able to see the whole thing, including many other exclusive benefits.

You don't have access to this post, but if you become a premium member, you'll be able to see the whole thing, including many other exclusive benefits.

You May Like These Articles

Medsider Premium

Become a premium member and unlock access to exclusive Medsider benefits.

Medsider Mentors

Medsider Mentors

Medsider Playbooks

Medsider Playbooks

Playbook

A Guide to Widespread Adoption in Medtech

In medtech, developing novel, impactful technology is often just the starting line. The real race begins when you try to integrate your solution into the often-resistant healthcare system – a hurdle that has tripped up countless promising companies. Here are the key strategies and lessons from five veterans in the medtech space on how to overcome this hurdle.

Copyright © Medsider 2024 • All rights reserved.

Subscribe

Sign In

Suggest a Guest

Copyright © Medsider 2024 • All rights reserved.

Subscribe

Sign In

Suggest a Guest

Copyright © Medsider 2024 • All rights reserved.

Subscribe

Sign In

Suggest a Guest